Abstract
Abstract
Background
Hepatocellular carcinoma (HCC) represents the sixth most common cancer worldwide and the fourth in Egypt. Persistent inflammation and specific somatic mutations in driving genes play a major role in the development of HCC. One of these somatic mutations is CTNNB1 mutations with subsequent activation of β-catenin in HCC, associated with a risk of malignant transformation. In this study, we investigate the clinical utility of peripheral blood circulating tumor DNA (ctDNA) CTNNB1 (rs121913407) in HCC patients compared to pathological chronic hepatitis C virus (HCV) patients and healthy controls.
Methods
Our study is a case-control study at the Ain Shams Centre for Organ Transplantation, Ain Shams University Hospitals, enrolling twenty-eight adult HCC patients (twelve early HCC patients and sixteen advanced HCC patients), ten patients with chronic hepatitis C as a disease control group, and ten healthy controls. We collected plasma and stored at −80 °C. We detected mutations in the gene locus CTNNB1 rs121913407 by real-time PCR.
Results
All of our studied cases (early and advanced HCC) in addition to HCV and healthy control groups were CTNNB1 wild (TT) genotype. There was statistical significant difference between early and late cases of HCC as regards AFP and AST.
Conclusions
None of our recruited subjects showed CTNNB1 rs121913407 gene mutation. Further studies on larger number of patients are needed to clarify and confirm the clinical utility of CTNNB1 single-nucleotide polymorphism in the pathogenesis of HCC related to HCV in Egyptian population.
Funder
Science and Technology Development Fund
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Tawfik M, Gomaa A, Hassan E, Fouad E (2019) Presentation of hepatocelluler carcinoma at time of discovery in Egyptian patients with liver cirrhosis secondary to chronic hepatitis C. FUMJ 4(1):1–10
2. Yehia SA, Morad WS, Hendy OM, Dorgham LS (2020) Effect of health education intervention on hepatocellular carcinoma risk factor prevention in Menoufia Governorate. Egypt Egyptian Liver J 10:1-8.
3. Lombardo D, Saitta C, Giosa D et al (2020) Frequency of TP53, CTNNB1, and TERT promoter mutations in patients with hepatocellular carcinoma. Dig Liver Dis 52:e52–e53
4. Pawlotsky J-M, Negro F, Aghemo A et al (2018) EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69(2):461–511
5. Mocan T, Simão A, Castro R et al (2020) Liquid biopsies in hepatocellular carcinoma: are we winning? J Clin Med 9(5):1541